Skip to content

January 2026

DMT

What January 2026's 11 new studies found, synthesized from the papers below. All DMT research →

The synthesis

Synthesized from 3 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for DMT, dimethyltryptamine, 5-MeO-DMT, then ranked by relevance.

Research on DMT published in January 2026 shows that a single dose can reverse anhedonia and cognitive deficits in a mouse model of depression, and that DMT has neuroprotective effects in a rat model of spinal injury. A micro-phenomenological study in humans found that DMT-induced immersion and perceived presences follow a structured, hierarchical developmental pattern. However, the evidence is limited to animal models and a single human study with a small sample, and no clinical trials in humans were reported.

Confidence in the evidence

Low-Moderate
  • Only one human study (n=23) with micro-phenomenological interviews; no RCTs in humans.
  • Two animal studies (mice, rats) with small sample sizes (n not fully reported for one).
  • Findings are consistent in direction (positive effects) but limited to preclinical models.
  • No clinical efficacy or safety data in humans for DMT itself (5-MeO-DMT studies are separate).
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

Single-dose DMT reverses anhedonia and cognitive deficits via restoration of neurogenesis in a stress-induced depression model. 2026
Supports

A single dose of DMT reversed anhedonia and cognitive deficits in stressed mice, outperforming chronic fluoxetine, and increased adult-born granule cell integration.

preclinical animal study

Combined Neuroprotective Effects of N,N‐Dimethyltryptamine and Ventral Root Reimplantation Following Spinal Root Avulsion in Rats 2026
Supports

DMT at 1 mg/kg combined with surgical reimplantation enhanced motor neuron survival, reduced glial reactivity, and preserved synaptic boutons after spinal root avulsion.

preclinical animal study

Micro-phenomenology of immersion and perceived presences under DMT. 2026
Supports

Micro-phenomenological analysis revealed that DMT-induced immersion follows a structured continuum, with bodily effects preceding visual/auditory ones, and perceived presences emerging only after multisensory integration.

qualitative micro-phenomenological study Sample size: 23

Points of agreement

  • DMT shows potential therapeutic effects in preclinical models (antidepressant-like, neuroprotective).
  • DMT induces structured, immersive experiences with perceived presences in humans.

Conflicts

  • No direct conflicts; studies address different aspects (animal behavior, neuroprotection, human phenomenology).

Gaps

  • No human clinical trials on DMT efficacy or safety were reported.
  • Durability of effects and long-term outcomes are unstudied.
  • Role of the psychedelic experience vs. direct pharmacological action remains unclear.
  • Small sample sizes and lack of blinding in the human study.
  • No studies on DMT in clinical populations (e.g., depression, PTSD) in this period.
Browse these studies in the library